Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Non-Small Cell Lung Cancer
14 articles
Immunotherapy Boost: New Hope for Early-Stage Lung Cancer Patients
Meta-analysis shows neoadjuvant immunotherapy plus chemo improves outcomes in resectable NSCLC patients.
Setback in Lung Cancer Trial: Immunotherapy-Radiation Combo Raises Concerns
Phase 2 trial of durvalumab with radiation for NSCLC halted early due to safety and efficacy issues.
Immune Checkpoint Inhibitors in MS Patients: Low Relapse Risk, Promising Outlook
Study shows low relapse risk for MS patients on immune checkpoint inhibitors, suggesting safe use with precautions.
Unmasking the Risk Factors: New Insights into Immune-Mediated Hepatotoxicity in Cancer Immunotherapy
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
Immune Checkpoint Inhibitor Rechallenge: A New Hope for Cancer Patients
Meta-analysis shows ICI rechallenge may be safe and effective for some cancer patients who stopped treatment
Sex and Side Effects: New Study Explores Gender Differences in Cancer Immunotherapy
Meta-analysis investigates sex-based differences in adverse events for cancer patients on immunotherapy
Breakthrough Combo Therapy Outperforms Standard Treatment in Advanced Lung Cancer
New drug combination shows promising results in treating advanced EGFR-mutated lung cancer patients.
Capmatinib Shines in METex14 NSCLC: GEOMETRY mono-1 Trial Unveils Promising Results
Final results from GEOMETRY mono-1 trial show capmatinib's efficacy in METex14 NSCLC, especially first-line.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Early-Stage Lung Cancer
Pembrolizumab plus chemotherapy improves survival in resectable early-stage non-small cell lung cancer.
New Hope in Lung Cancer: Dostarlimab Rivals Pembrolizumab in First-Line Treatment
Phase II trial shows dostarlimab plus chemo matches pembrolizumab efficacy for metastatic NSCLC patients.
FLAURA2 Trial: Osimertinib Plus Chemo Boosts Survival in EGFR-Mutated Lung Cancer
Combining osimertinib with chemotherapy significantly improves progression-free survival in NSCLC patients.
Amivantamab Plus Chemotherapy: A New Frontline Treatment for NSCLC with EGFR Exon 20 Insertions
Study shows amivantamab-chemotherapy combo significantly improves outcomes in NSCLC with EGFR mutations